NOVARTIS GENE THERAPIES

Novartis Gene Therapies provides links to third-party sites as a convenience and is not responsible for the content of these sites... ZOLGENSMA is a gene therapy that stops SMA progression with a one-time-only dose. It targets the genetic root cause of SMA, mutations in the SMN1 gene, by introducing a fully functional copy of the human SMN gene. 



Also known as: Novartis Gene Therapies, Inc